A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Jul 14, 2011

Keywords

ClinConnect Summary

Aromatic L-amino acid decarboxylase (AADC) is an enzyme responsible for the final step in the synthesis of neurotransmitters dopamine and serotonin. AADC deficiency is a rare genetic disorder. Taiwanese carry a high prevalence of AADC deficiency due to the founder mutation IVS6+4 A\>T, and patients usually die before the age 5-6 years due to severe motor dysfunction.

Gene therapy with adeno-associated virus (AAV) serotype 2 (AAV2) driven human AADC (hAADC) has been tested in both animal models and Phase I clinical trials of Parkinson disease. We have done a compassionate treatment of 8 pat...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. With a confirmed diagnosis of AADC, including cerebrospinal fluid analysis to show reduced levels of neurotransmitter metabolites, HVA and 5-HIAA, and higher L-Dopa, together with more than one mutation within AADC gene.
• • 2. Classical clinical characteristics of AADC deficiency, such as oculogyric crises, hypotonia and developmental retardation.
• • 3. The sick child has to be over 2 years old or a head circumference big enough for surgery.
• • 4. Participating patients must cooperate completely for all evaluations and examinations before, during and after the whole trial.
• • 5. Parents or guardians must sign to agree on this informed consent.
• • Exclusion criteria
• • 1. Significant brain structure abnormality
• • 2. Patients with any health or neurological doubts that may increase the risk of surgery cannot join this trial. PI has the right to evaluate the feasibility of subjects for this trial based on his/her health condition.
• • 3. Since high-level neutralizing antibodies may disturb the therapeutic effect of gene therapy, patients with anti-AAV2 neutralizing antibody titer over 1,200 folds or an ELISA OD over 1 cannot be enrolled into this trial.
• • 4. Subjects enrolled in this clinical trial cannot take any medications that may affect this trial.

Trial Officials